Tradestie Institutional Equity Comparison Engine

ENTX vs LYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENTX Overall Edge

ENTX Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ENTX N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner ENTX
Op Margin 0.0% vs -25032.0% ยท YoY -100.0% vs -87.2%
Momentum & Technical Winner ENTX
1Y +11.1% vs -94.3% ยท 52W Pos 64% vs 1%
Options & Structure Winner ENTX
CONSOLIDATION (32nd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap $541.6M
1M Return +2.38%
1Y Return +11.07%
Forward P/E N/M
Unified AI Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTX +11.07% LYRA -94.34% Spread: +36.96 pp (ENTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ENTX Revenue LYRA Revenue ENTX Op. Margin LYRA Op. Margin Margin Edge
FY2020 $0M N/A -3059.7% N/A ENTX
FY2021 $0M $0M -2139.6% -15303.5% ENTX
FY2022 $0M $0M -9714.2% -4131.0% LYRA
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 $0M $0M -5295.6% -6280.8% ENTX
FY2025 $0M $0M -27450.0% -7794.5% LYRA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTX (6) vs LYRA (1)
Institutional Metric ENTX LYRA Criterion Row Winner
Market Capitalization Scale $541.6M $2.3M Larger Scale ENTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% -87.2% Higher Growth LYRA
Operating Margin (TTM) Profitability 0.0% -25032.0% Higher Margin ENTX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -20.3% -404.5% Higher ROE ENTX
52-Week Range Position Momentum 64% ($1โ€“$4) 1% ($0โ€“$38) Stronger Trend ENTX
Beta / 30D Volatility Risk Regime 1.07ฮฒ ยท 45% Vol 0.33ฮฒ ยท 248% Vol Lower Realized Risk ENTX
Unified Institutional Score Composite Signal 53.5 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite ENTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTX vs LYRA Buy Guide
ENTX CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 32nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.